Compare ACMR & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACMR | RCUS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | 2017 | 2018 |
| Metric | ACMR | RCUS |
|---|---|---|
| Price | $56.19 | $25.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $50.00 | $31.90 |
| AVG Volume (30 Days) | 981.0K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | $74,643,000.00 | ★ $247,000,000.00 |
| Revenue This Year | $29.37 | N/A |
| Revenue Next Year | $23.16 | $45.62 |
| P/E Ratio | $39.34 | ★ N/A |
| Revenue Growth | ★ 104.47 | N/A |
| 52 Week Low | $17.32 | $7.06 |
| 52 Week High | $71.65 | $28.72 |
| Indicator | ACMR | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 66.10 | 59.94 |
| Support Level | $49.37 | $19.62 |
| Resistance Level | $70.56 | N/A |
| Average True Range (ATR) | 2.46 | 1.56 |
| MACD | 1.33 | 0.30 |
| Stochastic Oscillator | 93.01 | 61.22 |
ACM Research Inc supplies capital equipment developed for the semiconductor industry. The company focuses on developing differentiated process solutions that enable effective particle removal, uniform material deposition, and reliable process control for the fabricators of integrated circuits. Its product offerings include wet-cleaning, plating, furnace, PECVD, track, and other front-end processing equipment. Additionally, it develops, manufactures, and sells a range of packaging equipment to wafer assembly and packaging customers. Geographically, the company generates maximum revenue from its customers in Mainland China, and the rest from other regions.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.